For the quarter ending 2026-03-31, PRME made $856K in revenue. -$49,122K in net income. Net profit margin of -5738.55%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 856 | 838 | 1,225 | 1,115 |
| Research and development | 34,105 | 34,709 | 43,990 | 41,375 |
| General and administrative | 17,405 | 14,737 | 11,208 | 13,117 |
| Total operating expenses | 51,510 | 49,446 | 55,198 | 54,492 |
| Loss from operations | -50,654 | -48,608 | -53,973 | -53,377 |
| Interest income | 1,021 | 1,083 | 1,141 | 743 |
| Accretion (amortization) of investments | 460 | 858 | 752 | 530 |
| Change in fair value of short-term investment related party | 0 | 539 | 1,454 | -505 |
| Other income, net | 51 | 49 | 44 | 18 |
| Total other income, net | 1,532 | 2,529 | 3,391 | 786 |
| Net loss before income taxes | - | - | - | -52,591 |
| Provision for income taxes | - | - | - | 0 |
| Net loss attributable to common stockholders, basic | -49,122 | -46,079 | -50,582 | -52,591 |
| Net loss attributable to common stockholders, diluted | -49,122 | - | -50,582 | -52,591 |
| Basic EPS | -0.28 | -0.264 | -0.32 | -0.41 |
| Diluted EPS | -0.28 | -0.264 | -0.32 | -0.41 |
| Basic Average Shares | 177,096,225 | 174,460,517 | 160,503,183 | 129,185,918 |
| Diluted Average Shares | 177,096,225 | 174,460,517 | 160,503,183 | 129,185,918 |
Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME)